Evidence map›Paper›PMID 40370911›Full record

ArticleCureus2025

Bilateral Spontaneous Pneumothorax in a Patient With Metastatic Leiomyosarcoma Receiving Pazopanib: A Case Report.

Maria Konstantinidou, Christina Chrysanthi Theocharidou, Anastasia Dimaki, Christos Emmanouilides, Fotini Ampatzidou

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Maria KonstantinidouDepartment of Respiratory Medicine, General Hospital of Thessaloniki "G. Papanikolaou", Thessaloniki, GRC.
Christina Chrysanthi TheocharidouIntensive Care Unit, General Hospital of Thessaloniki "G. Papanikolaou", Thessaloniki, GRC.
Anastasia DimakiIntensive Care Unit, General Hospital of Thessaloniki "G. Papanikolaou", Thessaloniki, GRC.
Christos EmmanouilidesDepartment of Oncology, Interbalkan Medical Center, Pylaia, GRC.
Fotini AmpatzidouIntensive Care Unit, General Hospital of Thessaloniki "G. Papanikolaou", Thessaloniki, GRC.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pneumothorax can be a rare but significant adverse event in patients with sarcoma and pulmonary metastases. This case report presents an instance of bilateral pneumothorax in a patient with metastatic leiomyosarcoma treated with pazopanib. A 74-year-old man with a history of grade 3 leiomyosarcoma and lung metastases was admitted with severe respiratory distress. He had been receiving pazopanib therapy following previous treatment with high-dose ifosfamide, doxorubicin, and radiotherapy. Imaging revealed bilateral pneumothorax, and the patient subsequently experienced respiratory arrest requiring immediate resuscitation measures including needle decompression followed by chest tube placement. The patient had experienced a unilateral pneumothorax two months prior to this presentation, which had resolved with standard interventions. While the bilateral pneumothorax eventually resolved after nine days of chest tube drainage, the patient exhibited no neurological recovery following the arrest, with brain imaging revealing bilateral cortical laminar necrosis. His clinical condition deteriorated significantly after 28 days in the intensive care unit (ICU), culminating in septic shock and death. This case highlights a serious pulmonary complication that can occur during the treatment of metastatic leiomyosarcoma, particularly in patients with lung metastases. The relationship between the development of pneumothorax and pazopanib therapy, along with the challenges in management and poor clinical outcome, merits consideration when treating similar patients.

Indexed as

adverse eventbilateral pneumothoraxleiomyosarcomapazopanibpulmonary metastasestyrosine kinase inhibitor

Identifiers

PMID40370911
PMCPMC12076265

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.